A Phase 1 b Study of the Selective HDAC Inhibitor Mocetinostat in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma
Brief description of study
If you have been diagnosed with melanoma that cannot be surgically removed or has spread to other parts of your body, you may be qualified to participate in this phase 1b study evaluating the safety of the investigational drug Mocetinostat. together with ipilimumab and nivolumab for patients with advanced melanoma. The main goal of this study is to evaluate the safety of the combination of all three drugs when treating patients with unresectable Stage III or Stage IV melanoma.
Clinical Study Identifier: s17-00861
ClinicalTrials.gov Identifier: NCTs17-00861
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
